Rationally designed peptides relieve ischemic stroke by targeting TRPM2 intramolecular interactions.
Yao J, You Q, Liu X, Zhen W, Fang M, Luo Y, Wu J, Mai Z, Yu P, Yang F, Yang W · 2026 · Pharmacological research (2026); PMID 41932669
Study data at a glance
- Participants or experimental model
- TRPM2 electrophysiology and calcium imaging; mouse ischemic-stroke model
- Reported results
- M2IP inhibited TRPM2 at submicromolar concentrations in experimental assays and reduced brain injury in a mouse stroke model. It targets an inter-subunit interface involved in channel activation.
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- International comparison, not a confirmed Russian development. Abstract-level findings do not establish human benefit; full dosing, effect sizes and bias appraisal remain needed.
- Indexed abstract checked; complete methods, tables and independent replication have not been appraised.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Review depth: Indexed abstract checked
Source access and review scope
Original publication metadata and indexed abstract checked via Europe PMC; no full-text appraisal.
Recorded source-check date: 2026-10-17. This date does not imply a completed systematic review.
Citation and original source
Original source: Yao J, You Q, Liu X, Zhen W, Fang M, Luo Y, Wu J, Mai Z, Yu P, Yang F, Yang W. Rationally designed peptides relieve ischemic stroke by targeting TRPM2 intramolecular interactions. Pharmacological research (2026); PMID 41932669 2026.
Molekul research summary: https://molekul.io/research/oct17-41932669. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry